Dr. Powles on Bevacizumab Plus Atezolizumab in Kidney Cancer

Thomas Powles, MD
Published: Wednesday, Jul 19, 2017



Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

The IMmotion150 is the first randomized study in frontline kidney cancer investigating immune checkpoint inhibitors, states Powles.
 
SELECTED
LANGUAGE


Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

The IMmotion150 is the first randomized study in frontline kidney cancer investigating immune checkpoint inhibitors, states Powles.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x